Administration of a neutralizing anti-CD278 mAb reduced human Treg proportions and numbers and improved CD4+ T cell proliferation therefore highlighting the crucial implication of innate immunity in treatment efficacy, opening new perspectives for the treatment of breast cancer (125). This evidence concerns the gene ICOS and breast carcinoma.